Optimer Pharma could earn $90 million from new Astellas deal

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major Astellas Pharma (TOY: 4503) for the latter to develop and commercialize Dificid (fidaxomicin) in Japan for the treatment of Clostridium difficile Infection (CDI).

As a result, Optimer will receive a one-time, up-front cash payment of $20 million from Astellas. Optimer is also eligible to receive additional cash payments of up to $70 million on the achievement of certain regulatory and commercial milestones. Optimer is further entitled to receive payments from Astellas that provide a return resulting in a double digit percent of Astellas net sales in the territory. Astellas is responsible for all future costs associated with the development and commercialization of fidaxomicin in Japan.

Already has rights in other markets